

Emilia Montagna

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2578555/emilia-montagna-publications-by-year.pdf>

Version: 2024-04-18

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53
papers

1,337
citations

21
h-index

36
g-index

56
ext. papers

1,583
ext. citations

3.6
avg, IF

3.73
L-index

#	Paper	IF	Citations
53	A molecular reappraisal of matrix-producing breast metaplastic carcinoma highlighted by PLAG1 and MYC rearrangements.. <i>Tumori</i> , 2022 , 3008916221080190	1.7	
52	Low-risk triple-negative breast cancers: Clinico-pathological and molecular features.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 172, 103643	7	5
51	Oncoplastic Breast-Conserving Surgery for Synchronous Multicentric and Multifocal Tumors: Is It Oncologically Safe? A Retrospective Matched-Cohort Analysis. <i>Annals of Surgical Oncology</i> , 2021 , 1	3.1	1
50	Systematic review and meta-analysis of post-progression outcomes in ER+/HER2- metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials. <i>ESMO Open</i> , 2021 , 6, 100332	6	2
49	ASO Visual Abstract: Oncoplastic Breast-Conserving Surgery for Synchronous Multicentric and Multifocal Tumors: is it Oncologically Safe? A Retrospective Matched-Cohort Analysis. <i>Annals of Surgical Oncology</i> , 2021 , 28, 764-765	3.1	0
48	Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer Survivors. <i>Frontiers in Oncology</i> , 2021 , 11, 705927	5.3	2
47	Systematic review and meta-analysis of post-progression outcomes in ER+/HER2- metastatic breast cancer after treatment with endocrine therapy and CDK 4/6 inhibitors within randomized clinical trials.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1059-1059	2.2	
46	Metaplastic breast cancer: Prognostic and therapeutic considerations. <i>Journal of Surgical Oncology</i> , 2021 , 123, 61-70	2.8	14
45	Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 804-812	3.6	38
44	Assessing Predictors of Tamoxifen Nonadherence in Patients with Early Breast Cancer. <i>Patient Preference and Adherence</i> , 2021 , 15, 2051-2061	2.4	1
43	Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study. <i>Breast Cancer Research and Treatment</i> , 2021 , 190, 415-424	4.4	0
42	Management of breast cancer patients during the peak of the COVID 19 pandemic. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 2694-2695	3.6	0
41	Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations. <i>Breast</i> , 2021 , 59, 94-101	3.6	3
40	Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapy. <i>Radiotherapy and Oncology</i> , 2021 , 163, 128-135	5.3	1
39	Pegylated Liposomal Doxorubicin (Caelyx) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial.. <i>Current Oncology</i> , 2021 , 28, 5167-5178	2.8	1
38	Breast Adjuvant Radiotherapy Amid the COVID-19 Crisis in a Hub Cancer Center, Lombardy, Italy. <i>Breast Care</i> , 2020 , 5, 1-7	2.4	1
37	Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e12570-e12570	2.2	

36	Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy. <i>Breast</i> , 2020 , 53, 138-142	3.6	4
35	Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study. <i>Breast Cancer Research and Treatment</i> , 2020 , 184, 783-795	4.4	1
34	Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study. <i>Breast</i> , 2019 , 48, 7-16	3.6	24
33	Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines. <i>British Journal of Cancer</i> , 2019 , 121, 325-331	8.7	12
32	Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919894105	5.4	10
31	Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer. <i>Clinical Breast Cancer</i> , 2018 , 18, 328-335	3	10
30	Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and Outcomes. <i>Clinical Breast Cancer</i> , 2018 , 18, e401-e405	3	10
29	Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists?. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 805-814	3.5	1
28	Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): Final results of the VICTOR-6 study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e13076-e13076	2.2	
27	Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial. <i>Breast Care</i> , 2018 , 13, 177-181	2.4	21
26	Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial. <i>Cancer Letters</i> , 2017 , 400, 276-281	9.9	26
25	Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy. <i>Breast</i> , 2017 , 34, 83-88	3.6	17
24	Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2015 , 15, 259-65	3	29
23	Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2015 , 26, 307-13	10.3	32
22	Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study. <i>Clinical Breast Cancer</i> , 2015 , 15, e257-62	3	1
21	Outcome and Medial Presentation of Breast Cancer: European Institute of Oncology Experience. <i>Clinical Breast Cancer</i> , 2015 , 15, 440-7	3	1
20	Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression. <i>Clinical Breast Cancer</i> , 2014 , 14, 258-64	3	31
19	Metronomic therapy and breast cancer: a systematic review. <i>Cancer Treatment Reviews</i> , 2014 , 40, 942-50	4.4	39

18	Whole-body magnetic resonance imaging, metastatic breast cancer and pregnancy: a case report. <i>Breast</i> , 2014 , 23, 295-6	3.6	4
17	Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. <i>Annals of Oncology</i> , 2013 , 24, 661-8	10.3	81
16	The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?. <i>Cancer Treatment Reviews</i> , 2013 , 39, 886-90	14.4	9
15	Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. <i>Clinical Breast Cancer</i> , 2013 , 13, 31-9	3	99
14	Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. <i>Breast</i> , 2012 , 21, 309-13	3.6	21
13	Outcome of special types of luminal breast cancer. <i>Annals of Oncology</i> , 2012 , 23, 1428-36	10.3	79
12	Invasive lobular breast cancer: subtypes and outcome. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 713-23	4.4	94
11	Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. <i>Clinical Breast Cancer</i> , 2012 , 12, 207-14	3	52
10	Breast cancer subtypes and outcome after local and regional relapse. <i>Annals of Oncology</i> , 2012 , 23, 324-31	10.3	48
9	Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer. <i>Breast</i> , 2011 , 20, 34-8	3.6	7
8	Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation. <i>Breast Cancer Research and Treatment</i> , 2011 , 129, 867-75	4.4	40
7	Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report. <i>Annals of Oncology</i> , 2010 , 21, 667-668	10.3	7
6	Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (. <i>Annals of Oncology</i> , 2010 , 21, 1974-1981	10.3	161
5	Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 689-99	4.4	55
4	A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer. <i>Annals of Oncology</i> , 2009 , 20, 1178-84	10.3	33
3	Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. <i>Breast Cancer Research and Treatment</i> , 2009 , 116, 317-28	4.4	150
2	Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure. <i>Breast Cancer Research and Treatment</i> , 2009 , 118, 385-94	4.4	28
1	Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer. <i>British Journal of Cancer</i> , 2008 , 98, 1745-52	8.7	14

